Absolute and Relative Contraindications to IV rt-PA for Acute Ischemic Stroke

The Neurohospitalist

Volumn 5, Issue 3, 2015, Pages 110-121

  Fugate, Jennifer E ^a   Rabinstein, Alejandro A ^a  

^a MAYO CLINIC   (United States)

Author keywords

acute stroke; contraindications; thrombolytic therapy; tissue plasminogen activator

Indexed keywords

EID: 84992884507     PISSN: 19418744     EISSN: 19418752     Source Type: Journal    
DOI: 10.1177/1941874415578532     Document Type: Review

References (103)

1. Jauch EC Saver JL Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013; 44(3):870–947.
2. Meretoja A Putaala J Tatlisumak T, et al. Off-label thrombolysis is not associated with poor outcome in patients with stroke. Stroke. 2010; 41(7):1450–1458.
3. Kvistad CE Logallo N Thomassen L, et al. Safety of off-label stroke treatment with tissue plasminogen activator. Acta Neurol Scand. 2013; 128(1):48–53.
4. Kato H Izumiyama M Izumiyama K Takahashi A Itoyama Y. Silent cerebral microbleeds on T2*-weighted MRI: correlation with stroke subtype, stroke recurrence, and leukoaraiosis. Stroke. 2002; 33(6):1536–1540.
5. Fiehler J Albers GW Boulanger JM, et al. Bleeding risk analysis in stroke imaging before thromboLysis (BRASIL): pooled analysis of T2*-weighted magnetic resonance imaging data from 570 patients. Stroke. 2007; 38(10):2738–2744.
6. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995; 333(24):1581–1587.
7. Ahmed N Wahlgren N Brainin M, et al. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR). Stroke. 2009; 40(7):2442–2449.
8. Demchuk AM Tanne D Hill MD, et al. Predictors of good outcome after intravenous tPA for acute ischemic stroke. Neurology. 2001; 57(3):474–480.
9. Larrue V von Kummer RR Muller A Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke. 2001; 32(2):438–441.
10. Brott T Lu M Kothari R, et al. Hypertension and its treatment in the NINDS rt-PA Stroke Trial. Stroke. 1998; 29(8):1504–1509.
11. Albers GW Bates VE Clark WM Bell R Verro P Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000; 283(9):1145–1150.
12. Tsivgoulis G Saqqur M Sharma VK Lao AY Hill MD Alexandrov AV. Association of pretreatment blood pressure with tissue plasminogen activator-induced arterial recanalization in acute ischemic stroke. Stroke. 2007; 38(9):961–966.
13. Tanne D Kasner SE Demchuk AM, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation. 2002; 105(14):1679–1685.
14. Katzan IL Furlan AJ Lloyd LE, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA. 2000; 283(9):1151–1158.
15. Lopez-Yunez AM Bruno A Williams LS Yilmaz E Zurru C Biller J. Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage. Stroke. 2001; 32(1):12–16.
16. Guillan M Alonso-Canovas A Garcia-Caldentey J, et al. Off-label intravenous thrombolysis in acute stroke. Eur J Neurol. 2012; 19(3):390–394.
17. Breuer L Blinzler C Huttner HB Kiphuth IC Schwab S Kohrmann M. Off-label thrombolysis for acute ischemic stroke: rate, clinical outcome and safety are influenced by the definition of ‘minor stroke’. Cerebrovasc Dis. 2011; 32(2):177–185.
18. Topakian R Gruber F Fellner FA Haring HP Aichner FT. Thrombolysis beyond the guidelines: two treatments in one subject within 90 hours based on a modified magnetic resonance imaging brain clock concept. Stroke. 2005; 36(11):e162–e164.
19. Brunner F Tomandl B Schroter A, et al. Hemorrhagic complications after systemic thrombolysis in acute stroke patients with abnormal baseline coagulation. Eur J Neurol. 2011; 18(12):1407–1411.
20. Frank B Grotta JC Alexandrov AV, et al. Thrombolysis in stroke despite contraindications or warnings? Stroke. 2013; 44(3):727–733.
21. Giugliano RP McCabe CH Antman EM, et al. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. Am Heart J. 2001; 141(5):742–750.
22. Mazya M Egido JA Ford GA, et al. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score. Stroke. 2012; 43(6):1524–1531.
23. Xian Y Liang L Smith EE, et al. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. JAMA. 2012; 307(24):2600–2608.
24. European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008; 25(5):457–507.
25. Matute MC Masjuan J Egido JA, et al. Safety and outcomes following thrombolytic treatment in stroke patients who had received prior treatment with anticoagulants. Cerebrovasc Dis. 2012; 33(3):231–239.
26. Kim YD Lee JH Jung YH, et al. Safety and outcome after thrombolytic treatment in ischemic stroke patients with high-risk cardioembolic sources and prior subtherapeutic warfarin use. J Neurol Sci. 2010; 298(1-2):101–105.
27. Seet RC Zhang Y Moore SA Wijdicks EF Rabinstein AA. Subtherapeutic international normalized ratio in warfarin-treated patients increases the risk for symptomatic intracerebral hemorrhage after intravenous thrombolysis. Stroke. 2011; 42(8):2333–2335.
28. Ibrahim MM Sebastian J Hussain M, et al. Does current oral antiplatelet agent or subtherapeutic anticoagulation use have an effect on tissue-plasminogen-activator-mediated recanalization rate in patients with acute ischemic stroke? Cerebrovasc Dis. 2010; 30(5):508–513.
29. Prabhakaran S Rivolta J Vieira JR, et al. Symptomatic intracerebral hemorrhage among eligible warfarin-treated patients receiving intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol. 2010; 67(5):559–563.
30. Ruecker M Matosevic B Willeit P, et al. Subtherapeutic warfarin therapy entails an increased bleeding risk after stroke thrombolysis. Neurology. 2012; 79(1):31–38.
31. Vergouwen MD Casaubon LK Swartz RH, et al. Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator. Stroke. 2011; 42(4):1041–1045.
32. Miedema I Luijckx GJ De Keyser J Koch M Uyttenboogaart M. Thrombolytic therapy for ischaemic stroke in patients using warfarin: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2012; 83(5):537–540.
33. Coyle D Coyle K Cameron C, et al. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Value Health. 2013; 16(4):498–506.
34. Matute MC Guillan M Garcia-Caldentey J, et al. Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran. Thromb Haemost. 2011; 106(1):178–179.
35. De Smedt A De Raedt S Nieboer K De Keyser J Brouns R. Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran. Cerebrovasc Dis. 2010; 30(5):533–534.
36. Lee VH Conners JJ Prabhakaran S. Intravenous thrombolysis in a stroke patient taking dabigatran. J Stroke Cerebrovasc Dis. 2012; 21(8):916. e911–e912.
37. Marrone LC Marrone AC. Thrombolysis in an ischemic stroke patient on dabigatran anticoagulation: a case report. Cerebrovasc Dis. 2012; 34(3):246–247.
38. Sangha N El Khoury R Misra V Lopez G. Acute ischemic stroke treated with intravenous tissue plasminogen activator in a patient taking dabigatran with radiographic evidence of recanalization. J Stroke Cerebrovasc Dis. 2012; 21(8):917 e915–918.
39. Barreto AD Alexandrov AV Lyden P, et al. The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study. Stroke. 2012; 43(3):770–775.
40. Blommel ML Blommel AL. Dabigatran etexilate: a novel oral direct thrombin inhibitor. Am J Health Syst Pharm. 2011; 68(16):1506–1519.
41. Granger CB Alexander JH McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11):981–992.
42. Patel MR Mahaffey KW Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10):883–891.
43. Yong AW Morris Z Shuler K Smith C Wardlaw J. Acute symptomatic hypoglycaemia mimicking ischaemic stroke on imaging: a systemic review. BMC Neurol. 2012; 12: 139.
44. Ribo M Molina C Montaner J, et al. Acute hyperglycemia state is associated with lower tPA-induced recanalization rates in stroke patients. Stroke. 2005; 36(8):1705–1709.
45. Ribo M Molina CA Delgado P, et al. Hyperglycemia during ischemia rapidly accelerates brain damage in stroke patients treated with tPA. J Cerebral Blood Flow Metab. 2007; 27(9):1616–1622.
46. Bruno A Levine SR Frankel MR, et al. Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology. 2002; 59(5):669–674.
47. Demchuk AM Morgenstern LB Krieger DW, et al. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke. 1999; 30(1):34–39.
48. Saur D Kucinski T Grzyska U, et al. Sensitivity and interrater agreement of CT and diffusion-weighted MR imaging in hyperacute stroke. AJNR Am J Neuroradiol. 2003; 24(5):878–885.
49. von Kummer R Allen KL Holle R, et al. Acute stroke: usefulness of early CT findings before thrombolytic therapy. Radiology. 1997; 205(2):327–333.
50. Wardlaw JM Murray V Berge E Del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2009; 7: CD000213.
51. Hacke W Kaste M Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008; 359(13):1317–1329.
52. Hacke W Kaste M Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995; 274(13):1017–1025.
53. Hacke W Kaste M Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998; 352(9136):1245–1251.
54. Bamford J Sandercock P Dennis M Burn J Warlow C. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project—1981-86. 2. Incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry. 1990; 53(1):16–22.
55. Kammersgaard LP Jorgensen HS Reith J Nakayama H Pedersen PM Olsen TS. Short- and long-term prognosis for very old stroke patients. The Copenhagen Stroke Study. Age Ageing. 2004; 33(2):149–154.
56. Sandercock P Wardlaw JM Lindley RI, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet. 2012; 379(9834):2352–2363.
57. Mishra NK Ahmed N Andersen G, et al. Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. BMJ. 2010; 341: c6046.
58. Berrouschot J Rother J Glahn J Kucinski T Fiehler J Thomalla G. Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (> or =80 years) stroke patients. Stroke. 2005; 36(11):2421–2425.
59. Engelter ST Reichhart M Sekoranja L, et al. Thrombolysis in stroke patients aged 80 years and older: Swiss survey of IV thrombolysis. Neurology. 2005; 65(11):1795–1798.
60. Costello CA Campbell BC Perez de la Ossa N, et al. Age over 80 years is not associated with increased hemorrhagic transformation after stroke thrombolysis. J Clin Neurosci. 2012; 19(3):360–363.
61. Sylaja PN Cote R Buchan AM Hill MD. Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study. J Neurol Neurosurg Psychiatry. 2006; 77(7):826–829.
62. Ringleb PA Schwark C Kohrmann M, et al. Thrombolytic therapy for acute ischaemic stroke in octogenarians: selection by magnetic resonance imaging improves safety but does not improve outcome. J Neurol Neurosurg Psychiatry. 2007; 78(7):690–693.
63. Mouradian MS Senthilselvan A Jickling G, et al. Intravenous rt-PA for acute stroke: comparing its effectiveness in younger and older patients. J Neurol Neurosurg Psychiatry. 2005; 76(9):1234–1237.
64. van Oostenbrugge RJ Hupperts RM Lodder J. Thrombolysis for acute stroke with special emphasis on the very old: experience from a single Dutch centre. J Neurol Neurosurg Psychiatry. 2006; 77(3):375–377.
65. Smith EE Fonarow GC Reeves MJ, et al. Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from get with the guidelines-stroke. Stroke. 2011; 42(11):3110–3115.
66. Rajajee V Kidwell C Starkman S, et al. Early MRI and outcomes of untreated patients with mild or improving ischemic stroke. Neurology. 2006; 67(6):980–984.
67. Nedeltchev K Schwegler B Haefeli T, et al. Outcome of stroke with mild or rapidly improving symptoms. Stroke. 2007; 38(9):2531–2535.
68. Kim JT Park MS Chang J Lee JS Choi KH Cho KH. Proximal arterial occlusion in acute ischemic stroke with low NIHSS scores should not be considered as mild stroke. PLoS One. 2013; 8(8):e70996.
69. Smith EE Abdullah AR Petkovska I Rosenthal E Koroshetz WJ Schwamm LH. Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke. Stroke. 2005; 36(11):2497–2499.
70. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience. Ann Emerg Med. 2005; 46(3):243–252.
71. Kohrmann M Nowe T Huttner HB, et al. Safety and outcome after thrombolysis in stroke patients with mild symptoms. Cerebrovasc Dis. 2009; 27(2):160–166.
72. Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial. Stroke. 1997; 28(11):2119–2125.
73. Sylaja PN Dong W Grotta JC, et al. Safety outcomes of Alteplase among acute ischemic stroke patients with special characteristics. Neurocrit Care. 2007; 6(3):181–185.
74. Schonewille WJ Wijman CA Michel P, et al. Treatment and outcomes of acute basilar artery occlusion in the Basilar Artery International Cooperation Study (BASICS): a prospective registry study. Lancet Neurol. 2009; 8(8):724–730.
75. Shinton RA Gill JS Melnick SC Gupta AK Beevers DG. The frequency, characteristics and prognosis of epileptic seizures at the onset of stroke. J Neurol Neurosurg Psychiatry. 1988; 51(2):273–276.
76. Winkler DT Fluri F Fuhr P, et al. Thrombolysis in stroke mimics: frequency, clinical characteristics, and outcome. Stroke. 2009; 40(4):1522–1525.
77. Chernyshev OY Martin-Schild S Albright KC, et al. Safety of tPA in stroke mimics and neuroimaging-negative cerebral ischemia. Neurology. 2010; 74(17):1340–1345.
78. Zinkstok SM Engelter ST Gensicke H, et al. Safety of thrombolysis in stroke mimics: results from a multicenter cohort study. Stroke. 2013; 44(4):1080–1084.
79. Tsivgoulis G Alexandrov AV Chang J, et al. Safety and outcomes of intravenous thrombolysis in stroke mimics: a 6-year, single-care center study and a pooled analysis of reported series. Stroke. 2011; 42(6):1771–1774.
80. Forster A Griebe M Wolf ME Szabo K Hennerici MG Kern R. How to identify stroke mimics in patients eligible for intravenous thrombolysis? J Neurol. 2012; 259(7):1347–1353.
81. Selim M Kumar S Fink J Schlaug G Caplan LR Linfante I. Seizure at stroke onset: should it be an absolute contraindication to thrombolysis? Cerebrovasc Dis. 2002; 14(1):54–57.
82. Giraldo EA Khalid A Zand R. Safety of Intravenous Thrombolysis within 4.5 h of symptom onset in patients with negative post-treatment stroke imaging for cerebral infarction. Neurocrit Care. 2011; 15(1):76–79.
83. De Los Rios F Kleindorfer DO Guzik A, et al. Intravenous Fibrinolysis eligibility: a survey of stroke clinicians’ practice patterns and review of the literature. J Stroke Cerebrovasc Dis. 2014; 23(8):2130–2138.
84. De Silva DA Manzano JJ Chang HM Wong MC. Reconsidering recent myocardial infarction as a contraindication for IV stroke thrombolysis. Neurology. 2011; 76(21):1838–1840.
85. Dhand A Nakagawa K Nagpal S, et al. Cardiac rupture after intravenous t-PA administration in acute ischemic stroke. Neurocrit Care. 2010; 13(2):261–262.
86. Kasner SE Villar-Cordova CE Tong D Grotta JC. Hemopericardium and cardiac tamponade after thrombolysis for acute ischemic stroke. Neurology. 1998; 50(6):1857–1859.
87. Kremen SA Wu MN Ovbiagele B. Hemopericardium following intravenous thrombolysis for acute ischemic stroke. Cerebrovasc Dis. 2005; 20(6):478–479.
88. Garcia AM Egido JA Garcia ME Simal P. Thrombolysis for ischaemic stroke and glioblastoma multiforme: a case report. BMJ Case Rep. 2009; 2009.
89. Neil W Ovbiagele B. Intravenous thrombolysis in ischemic stroke patients with intracranial neoplasms: two cases and a literature review. Case Rep Med. 2011; 2011: 503758.
90. Etgen T Steinich I Gsottschneider L. Thrombolysis for ischemic stroke in patients with brain tumors. J Stroke Cerebrovasc Dis. 2014; 23(2):361–366.
91. Grimm SA DeAngelis LM. Intratumoral hemorrhage after thrombolysis in a patient with glioblastoma multiforme. Neurology. 2007; 69(9):936.
92. Jaffe R Reichman JM Weiss AT Zahger D. Thrombolysis in the presence of an intracranial meningioma. Chest. 1997; 111(1):258.
93. Rubinshtein R Jaffe R Flugelman MY Karkabi B Lewis BS. Thrombolysis in patients with a brain tumour. Heart. 2004; 90(12):1476.
94. Han S Chaya C Hoo GW. Thrombolytic therapy for massive pulmonary embolism in a patient with a known intracranial tumor. J Intensive Care Med. 2006; 21(4):240–245.
95. Mittal MK Seet RC Zhang Y Brown RD Jr Rabinstein AA. Safety of intravenous thrombolysis in acute ischemic stroke patients with saccular intracranial aneurysms. J Stroke Cerebrovasc Dis. 2013; 22(5):639–643.
96. Sheth KN Shah N Morovati T Hermann LD Cronin CA. Intravenous rt-PA is not associated with increased risk of hemorrhage in patients with intracranial aneurysms. Neurocrit Care. 2012; 17(6):199–203.
97. Kim JT Park MS Yoon W Cho KH. Detection and significance of incidental unruptured cerebral aneurysms in patients undergoing intravenous thrombolysis for acute ischemic stroke. J Neuroimaging. 2012; 22(2):197–200.
98. Alshekhlee A Li CC Chuang SY, et al. Does dementia increase risk of thrombolysis? A case-control study. Neurology. 2011; 76(18):1575–1580.
99. Edwards NJ Kamel H Josephson SA. The safety of intravenous thrombolysis for ischemic stroke in patients with pre-existing cerebral aneurysms: a case series and review of the literature. Stroke. 2012; 43(2):412–416.
100. Balami JS Hadley G Sutherland BA Karbalai H Buchan AM. The exact science of stroke thrombolysis and the quiet art of patient selection. Brain. 2013; 136(pt 12):3528–3553.
101. Saposnik G Cote R Rochon PA, et al. Care and outcomes in patients with ischemic stroke with and without preexisting dementia. Neurology. 2011; 77(18):1664–1673.
102. Busl KM Nogueira RG Yoo AJ Hirsch JA Schwamm LH Rost NS. Prestroke dementia is associated with poor outcomes after reperfusion therapy among elderly stroke patients. J Stroke Cerebrovasc Dis. 2013; 22(6):718–724.
103. Saposnik G Kapral MK Cote R, et al. Is pre-existing dementia an independent predictor of outcome after stroke? A propensity score-matched analysis. J Neurol. 2012; 259(11):2366–2375.